These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17922959)

  • 21. Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression.
    Su KP
    Asia Pac J Clin Nutr; 2008; 17 Suppl 1():151-7. PubMed ID: 18296325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How relevant is the ratio of dietary n-6 to n-3 polyunsaturated fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study.
    Griffin BA
    Curr Opin Lipidol; 2008 Feb; 19(1):57-62. PubMed ID: 18196988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feeding long-chain n-3 polyunsaturated fatty acids to obese leptin receptor-deficient JCR:LA- cp rats modifies immune function and lipid-raft fatty acid composition.
    Ruth MR; Proctor SD; Field CJ
    Br J Nutr; 2009 May; 101(9):1341-50. PubMed ID: 19079834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of inflammatory cytokines by omega-3 fatty acids.
    Kang JX; Weylandt KH
    Subcell Biochem; 2008; 49():133-43. PubMed ID: 18751910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of short-term oral administration of dietary marine oils in patients with inflammatory bowel disease and joint pain: a pilot study comparing seal oil and cod liver oil.
    Brunborg LA; Madland TM; Lind RA; Arslan G; Berstad A; Frøyland L
    Clin Nutr; 2008 Aug; 27(4):614-22. PubMed ID: 18374458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-chain polyunsaturated fat supplementation in children with low docosahexaenoic acid intakes alters immune phenotypes compared with placebo.
    Mazurak VC; Lien V; Field CJ; Goruk SD; Pramuk K; Clandinin MT
    J Pediatr Gastroenterol Nutr; 2008 May; 46(5):570-9. PubMed ID: 18493214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis.
    Bates D; Fawcett PR; Shaw DA; Weightman D
    Br Med J; 1978 Nov; 2(6149):1390-1. PubMed ID: 363236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging role of docosahexaenoic acid in neuroinflammation.
    Orr SK; Bazinet RP
    Curr Opin Investig Drugs; 2008 Jul; 9(7):735-43. PubMed ID: 18600579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of dietary omega-3 polyunsaturated fatty acids on experimental periodontitis in the mouse.
    Bendyk A; Marino V; Zilm PS; Howe P; Bartold PM
    J Periodontal Res; 2009 Apr; 44(2):211-6. PubMed ID: 19210341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotator cuff tendinopathy: is there a role for polyunsaturated Fatty acids and antioxidants?
    Lewis JS; Sandford FM
    J Hand Ther; 2009; 22(1):49-55; quiz 56. PubMed ID: 18950988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
    Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases.
    Simopoulos AP
    Exp Biol Med (Maywood); 2008 Jun; 233(6):674-88. PubMed ID: 18408140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nutrition in multiple sclerosis.
    Habek M; Hojsak I; Brinar VV
    Clin Neurol Neurosurg; 2010 Sep; 112(7):616-20. PubMed ID: 20444538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic cellular hypoxia as the prime cause of cancer: what is the de-oxygenating role of adulterated and improper ratios of polyunsaturated fatty acids when incorporated into cell membranes?
    Peskin BS; Carter MJ
    Med Hypotheses; 2008; 70(2):298-304. PubMed ID: 17656037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
    Longbrake EE; Racke MK
    Expert Rev Neurother; 2009 Mar; 9(3):319-21. PubMed ID: 19271940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a 'mind-body interface'?
    Su KP
    Neurosignals; 2009; 17(2):144-52. PubMed ID: 19190401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.